Patents Assigned to Pfizer
  • Patent number: 7456177
    Abstract: The present invention provides a compound having the structure of formula I: wherein R1 is hydrogen, (C1–C6) alkyl, unconjugated (C3–C6) alkenyl, benzyl, YC(?O)(C1–C6) alkyl or —CH2CH2—O—(C1–C4) alkyl; X is CH2 or CH2CH2; Y is (C2–C6) alkylene; Z is (CH2)m, CF2, or C(?O), where m is 0, 1 or 2; R2 and R3 are selected independently from hydrogen, halogen, —(C1–C6) alkyl optionally substituted with from 1 to 7 halogen atoms, and —O(C1–C6) alkyl optionally substituted with from 1 to 7 halogen atoms, or R2 and R3 each together with the atom to which it is connected independently form C(?O), S?O, S(?O)2, or N?O; and is a 5- to 7-membered monocyclic heteroaryl group selected from pyridinyl, pyridone, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, cinnolinyl, triazinyl, oxadiazolyl, thiadiazolyl and furazanyl groups.
    Type: Grant
    Filed: July 12, 2004
    Date of Patent: November 25, 2008
    Assignee: Pfizer Inc.
    Inventors: Martin P. Allen, Jotham W. Coe, Spiros Liras, Christopher J. O'Donnell, Brian T. O'Neill
  • Patent number: 7456164
    Abstract: The invention relates to 3- or 4-monosubstituted phenol and thiophenol derivatives of formula (I) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol and thiophenol derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: November 25, 2008
    Assignee: Pfizer, Inc
    Inventors: Patrick Bernardelli, Andrew Michael Cronin, Alexis Denis, Stephen Martin Denton, Henry Jacobelli, Mark Ian Kemp, Edwige Lorthiois, Fiona Rousseau, Delphine Serradeil-Civit, Fabrice Vergne
  • Publication number: 20080286302
    Abstract: The present invention provides safe vaccines and methods of preparing such vaccines. The vaccines of the present invention contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each of the two viruses or the encoding nucleic acids contains a mutation that confers a desirable phenotype and the mutations in the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations.
    Type: Application
    Filed: April 4, 2008
    Publication date: November 20, 2008
    Applicants: PFIZER INC., PFIZER PRODUCTS INC.
    Inventors: Siao-Kun Wan Welsh, Jay Gregory Calvert, Michael K. O'Hara, Xuemei Cao
  • Patent number: 7449462
    Abstract: Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: Het represents 2-pyridinyl or 2-pyrimidinyl; R1 represents H, C1-3 alkyl or a nitrogen-containing heterocyclic ring having 5 or 6 ring atoms; R2 represents H, benzyl or C1-3 alkyl; and R3 represents H, methyl, methoxy or chloro; are useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlesmerchz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease.
    Type: Grant
    Filed: January 11, 2005
    Date of Patent: November 11, 2008
    Assignee: Pfizer, Inc.
    Inventors: Justin S. Bryans, Patrick S. Johnson, Thomas Ryckmans, Alan Stobie
  • Patent number: 7449467
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: November 11, 2008
    Assignee: Pfizer Inc.
    Inventors: Chu-Biao Xue, Changsheng Zheng, Hao Feng, Michael Xia, Joseph Glenn, Ganfeng Cao, Brian W. Metcalf
  • Patent number: 7449616
    Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: November 11, 2008
    Assignee: Pfizer Inc.
    Inventors: Jaume Pons, Arnon Rosenthal
  • Publication number: 20080275101
    Abstract: The present invention relates to solid salt forms of the 3-pyrrole substituted 2-indolinone compound 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide. It also relates to polymorphs of the phosphate salt of the amide. The invention further relates to the use of the salts and polymorphs in the treatment of protein kinase related disorders.
    Type: Application
    Filed: September 8, 2006
    Publication date: November 6, 2008
    Applicants: PFIZER INC., PFIZER PRODUCTS INC.
    Inventors: Michael Hawley, Changquan C. Sun
  • Publication number: 20080274192
    Abstract: A pharmaceutical composition comprising the compound 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, or a pharmaceutically acceptable salt or solvate thereof, in an amorphous form.
    Type: Application
    Filed: May 8, 2006
    Publication date: November 6, 2008
    Applicant: PFIZER INC.
    Inventors: Dwayne Thomas Friesen, Douglas Alan Lorenz, Scott Wendell Smith
  • Publication number: 20080275235
    Abstract: Novel fused heteroaromatic compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)- signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Application
    Filed: July 23, 2008
    Publication date: November 6, 2008
    Applicants: PFIZER INC., PFIZER PRODUCTS INC.
    Inventors: Laura C. Blumberg, Michael J. Munchhof, Andrei Shavnya
  • Patent number: 7446121
    Abstract: Novel compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents are described. More specifically, potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (“HMG CoA reductase”) are described. Methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer's Disease, benign prostatic hypertrophy (BPH), diabetes and osteoporosis are also described.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: November 4, 2008
    Assignee: Pfizer Inc.
    Inventor: Jeffrey A. Pfefferkorn
  • Publication number: 20080269264
    Abstract: Crystalline forms of the p38 kinase inhibitor 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide is provided. Also provided are combinations and pharmaceutical compositions comprising the crystalline forms, and methods for the prophylaxis and/or treatment of a p38 kinase-mediated condition comprising administering to a subject a therapeutically effective amount of the crystalline forms.
    Type: Application
    Filed: October 3, 2005
    Publication date: October 30, 2008
    Applicant: PFIZER INC.
    Inventor: Jon G. Selbo
  • Publication number: 20080267942
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are agonists at the beta-2 adrenoceptor. They are useful as feed additives for livestock animals.
    Type: Application
    Filed: April 11, 2008
    Publication date: October 30, 2008
    Applicant: Pfizer Limited
    Inventors: Jessica Boyle, Ashley Edward Fenwick, David Morris Gethin, Catherine Frances McCusker
  • Patent number: 7442694
    Abstract: The present invention relates to a compounds of formula I: wherein A, B, D, E and F are defined herein; that are useful in treating central nervous system (CNS) diseases, disorders and conditions, such as but not limited to nicotine addiction, schizophrenia, depression, Alzheimer's disease, Parkinson's disease and ADHD. The present invention further comprises pharmaceutical compositions containing such compounds and methods of treatment comprising the use of such compounds.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: October 28, 2008
    Assignee: Pfizer Inc
    Inventors: Jotham W. Coe, Christopher J. O'Donnell, Brian T. O'Neill, Lawrence A. Vincent
  • Patent number: 7442795
    Abstract: A compound of formula (I), or a pharmaceutically acceptable derivative, wherein A, B, V, W, X, Y, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof.
    Type: Grant
    Filed: May 1, 2006
    Date of Patent: October 28, 2008
    Assignee: Pfizer Inc.
    Inventors: Justin Stephen Bryans, Patrick Stephen Johnson, Thomas Ryckmans, Alan Stobie
  • Patent number: 7442702
    Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: October 28, 2008
    Assignee: Pfizer Inc.
    Inventors: Kimberly O. Cameron, Bruce A. Lefker, Robert L. Rosati
  • Publication number: 20080262074
    Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid or solvates or hydrates thereof, as well as crystalline salts characterized by their X-ray powder diffraction pattern are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.
    Type: Application
    Filed: May 13, 2005
    Publication date: October 23, 2008
    Applicant: PFIZER, INC.
    Inventors: George Quallich, Peter Pawloy
  • Publication number: 20080261984
    Abstract: Use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pain condition selected from neuropathic pain, nociceptive pain, cancer pain, back pain, inflammatory pain, musculo-skeletal disorders, visceral pain, pain from strains/sprains, post-operative pain, posttraumatic pain, burns, renal colic, acute pain, central nervous system trauma, head pain, and orofacial pain, is disclosed. Use of (S,S)-reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of pain in a patient refractory to an alpha-2-delta ligand, and use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use as a mental performance or mood enhancer, are also disclosed.
    Type: Application
    Filed: May 27, 2005
    Publication date: October 23, 2008
    Applicant: Pfizer Inc.
    Inventors: Bernadette Hughes, Ian McKenzie, Malcolm John Stoker
  • Publication number: 20080262107
    Abstract: Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability.
    Type: Application
    Filed: May 18, 2005
    Publication date: October 23, 2008
    Applicant: PFIZER PRODUCTS INC.
    Inventors: Walter C. Babcock, Dwayne T. Friesen, David Keith Lyon, Warren Kenyon Miller, Daniel Tod Smithey
  • Patent number: 7439236
    Abstract: The present invention relates to compounds of formula I The substituent designations are as disclosed. At least one of B, Q, D and E is nitrogen. The present invention also provides a method of treating disorders of the Central Nervous System such as schizophrenia and cognitive dysfunction.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: October 21, 2008
    Assignee: Pfizer Inc
    Inventors: Brian Thomas O'Neill, Jotham Wadsworth Coe, Christopher J. O'Donnell
  • Patent number: 7439267
    Abstract: The present invention concerns a method of therapeutic prevention and treatment of a heart disease chosen from cardiac insufficiency and heart failure including the administration of an essential fatty acid containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), either alone or in combination with another therapeutic agent.
    Type: Grant
    Filed: January 17, 2006
    Date of Patent: October 21, 2008
    Assignee: Pfizer Italia S.R.L.
    Inventors: Francesco Granata, Franco Pamparana, Eduardo Stragliotto